van Dam P A, Hauspy J, Vanderheyden T, Sonnemans H, Spaepen A, Eggenstein G, Dirix L, Verkinderen L
Department of Obstetrics and Gynecology (Division Gynaecologic Oncology), Sint Augustinus Hospital, Antwerp, Belgium.
Int J Gynecol Cancer. 2003 Mar-Apr;13(2):182-6. doi: 10.1046/j.1525-1438.2003.13003.x.
The objective of this study is to determine the feasibility of intraoperative lymphatic mapping in patients with cervical carcinoma. Patients with early-stage cervical cancer, scheduled to undergo a Wertheims radical hysterectomy and pelvic lymphadenectomy, were eligible for the study. Technetium-99-m-labeled nanocolloid was injected intracervically at two locations around the tumor 3-6 hours before the operation. Images were recorded immediately and 2.5 hours later using a gamma camera. During the operation sentinel nodes (SLN) were identified using a handheld or laparoscopic gamma-detection probe (Navigator, Auto-Suture). After resection of the SLNs a standard pelvic (and para-aortic) lymphadenectomy was performed. The results of the histopathology of SLNs and non-SLNs were compared. The procedure was well tolerated by 24 of 25 patients. One or more SLN could be identified in 21 out of 25 patients. In one patient who was preoperatively irradiated, in two patients who had had a cone biopsy, and in one patient without previous interventions, no SLN could be detected. The mean time for identification was 5 minutes. In 16 patients, pathologic examination showed no metastatic disease in both SLNs and non-SLNs, whereas metastases were found in the SLN in five patients (in one case only SLN involved, four cases SLN and respectively 3, 11, 22 and 31 other positive nodes). This study shows that identification of SLNs in cancer of the uterine cervix is feasible with preoperatively administered 99mTc-labeled nanocolloid. To date, no false negative SLNs have been found, but expansion of the study is necessary to determine possible clinical application of this new technique.
本研究的目的是确定宫颈癌患者术中淋巴管造影的可行性。计划接受韦特海姆根治性子宫切除术和盆腔淋巴结清扫术的早期宫颈癌患者符合本研究条件。在手术前3 - 6小时,将99m锝标记的纳米胶体注射到肿瘤周围两个部位的宫颈内。使用γ相机立即和2.5小时后记录图像。在手术过程中,使用手持式或腹腔镜γ探测探头(Navigator,自动缝合器)识别前哨淋巴结(SLN)。切除SLN后,进行标准的盆腔(和腹主动脉旁)淋巴结清扫术。比较SLN和非SLN的组织病理学结果。25例患者中有24例对该手术耐受性良好。25例患者中有21例可识别出一个或多个SLN。在1例术前接受过放疗的患者、2例接受过锥形活检的患者和1例未接受过先前干预的患者中,未检测到SLN。识别的平均时间为5分钟。16例患者的病理检查显示SLN和非SLN均无转移疾病,而5例患者的SLN中发现有转移(1例仅SLN受累,4例SLN以及分别有3、11、22和31个其他阳性淋巴结)。本研究表明,术前给予99mTc标记的纳米胶体可在子宫颈癌中识别SLN。迄今为止,尚未发现假阴性的SLN,但有必要扩大研究以确定这项新技术的可能临床应用。